2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations
2011

IDH Mutations in Gliomas and Their Role in 2-Hydroxyglutarate Production

Sample size: 12 publication 10 minutes Evidence: high

Author Information

Author(s): Jin Genglin, Reitman Zachary J., Spasojevic Ivan, Batinic-Haberle Ines, Yang Jian, Schmidt-Kittler Oleg, Bigner Darell D., Yan Hai

Primary Institution: Duke University Medical Center

Hypothesis

Do IDH1 and IDH2 mutations in gliomas confer a dominant negative function or enhance 2-hydroxyglutarate production?

Conclusion

IDH mutations in gliomas do not exhibit dominant negative effects but significantly increase 2-hydroxyglutarate production.

Supporting Evidence

  • IDH1 R132 and IDH2 R172 mutations are common in gliomas.
  • Mutant IDH enzymes produce significantly higher levels of 2-hydroxyglutarate.
  • IDH mutations do not lower the activity of wild-type IDH enzymes.

Takeaway

Some brain tumors have changes in a gene that helps make a substance called 2-hydroxyglutarate, which can help the tumor grow.

Methodology

The study involved overexpressing IDH1 and IDH2 mutants in human glioma cells and measuring 2-hydroxyglutarate levels in culture media and tumor samples.

Limitations

The study primarily focused on specific IDH mutations and may not represent all glioma cases.

Participant Demographics

The study analyzed glioma samples from patients with various IDH mutations.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0016812

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication